Acorda Therapeutics Cdt Stock
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
| Ardelyx Inc. | 1.730% | -1.640% | -11.302% | 48.049% | 3.737% | -18.973% | - |
| Salarius Pharmaceuticals Inc. | -1.840% | 1.429% | 0.472% | -70.417% | -23.243% | -98.377% | -99.993% |
| Brainstorm Cell | -5.760% | -2.456% | -5.429% | -82.011% | 114.009% | -83.450% | - |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat